Breaking up is hard to do: why disinvestment in medical technology is harder than investment
- PMID: 22624634
- DOI: 10.1071/AH11032
Breaking up is hard to do: why disinvestment in medical technology is harder than investment
Abstract
Healthcare technology is a two-edged sword - it offers new and better treatment to a wider range of people and, at the same time, is a major driver of increasing costs in health systems. Many countries have developed sophisticated systems of health technology assessment (HTA) to inform decisions about new investments in new healthcare interventions. In this paper, we question whether HTA is also the appropriate framework for guiding or informing disinvestment decisions. In exploring the issues related to disinvestment, we first discuss the various HTA frameworks which have been suggested as a means of encouraging or facilitating disinvestment. We then describe available means of identifying candidates for disinvestment (comparative effectiveness research, clinical practice variations, clinical practice guidelines) and for implementing the disinvestment process (program budgeting and marginal analysis (PBMA) and related techniques). In considering the possible reasons for the lack of progress in active disinvestment, we suggest that HTA is not the right framework as disinvestment involves a different decision making context. The key to disinvestment is not just what to stop doing but how to make it happen - that is, decision makers need to be aware of funding disincentives.
Similar articles
-
Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: a systematic review.Int J Technol Assess Health Care. 2013 Apr;29(2):174-84. doi: 10.1017/S0266462313000068. Epub 2013 Mar 20. Int J Technol Assess Health Care. 2013. PMID: 23514665 Review.
-
Exploring policy-makers' perspectives on disinvestment from ineffective healthcare practices.Int J Technol Assess Health Care. 2008 Winter;24(1):1-9. doi: 10.1017/S0266462307080014. Int J Technol Assess Health Care. 2008. PMID: 18218163
-
Early assessment of medical technologies to inform product development and market access: a review of methods and applications.Appl Health Econ Health Policy. 2011 Sep 1;9(5):331-47. doi: 10.2165/11593380-000000000-00000. Appl Health Econ Health Policy. 2011. PMID: 21875163
-
Disinvestment Activities and Candidates in the Health Technology Assessment Community: An Online Survey.Int J Technol Assess Health Care. 2019 Jan;35(3):189-194. doi: 10.1017/S0266462319000229. Epub 2019 Apr 22. Int J Technol Assess Health Care. 2019. PMID: 31006390
-
Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.BMC Health Serv Res. 2018 Mar 1;18(1):148. doi: 10.1186/s12913-018-2941-0. BMC Health Serv Res. 2018. PMID: 29490647 Free PMC article. Review.
Cited by
-
Identifying potentially low value surgical care: A national ecological study in England.J Health Serv Res Policy. 2024 Oct;29(4):223-229. doi: 10.1177/13558196241252053. Epub 2024 May 9. J Health Serv Res Policy. 2024. PMID: 38725100 Free PMC article.
-
Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy.Appl Health Econ Health Policy. 2024 Jan;22(1):73-84. doi: 10.1007/s40258-023-00853-1. Epub 2023 Nov 11. Appl Health Econ Health Policy. 2024. PMID: 37950824
-
Did the evidence-based intervention (EBI) programme reduce inappropriate procedures, lessen unwarranted variation or lead to spill-over effects in the National Health Service?PLoS One. 2023 Sep 1;18(9):e0290996. doi: 10.1371/journal.pone.0290996. eCollection 2023. PLoS One. 2023. PMID: 37656701 Free PMC article.
-
Reporting of costs and economic impacts in randomized trials of de-implementation interventions for low-value care: a systematic scoping review.Implement Sci. 2023 Aug 21;18(1):36. doi: 10.1186/s13012-023-01290-3. Implement Sci. 2023. PMID: 37605243 Free PMC article. Review.
-
How health technology reassessment can support disinvestment in China's national drug reimbursement list.BMJ. 2023 Jun 15;381:e068917. doi: 10.1136/bmj-2021-068917. BMJ. 2023. PMID: 37321624 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
